Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial
November 07, 2026
November 07, 2026
DALLAS, Texas, Nov. 7 [Category: Health Care] -- The American Heart Association posted the following news release:
* * *
Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial
*
Research Highlights:
* Inflammation is a target for cardiovascular risk reduction. However, there are currently limited options to reduce inflammation among people with chronic kidney disease.
* . . .
* * *
Researchers say inflammation as a treatment target still important despite neutral results of ZEUS trial
*
Research Highlights:
* Inflammation is a target for cardiovascular risk reduction. However, there are currently limited options to reduce inflammation among people with chronic kidney disease.
* . . .